Credits: Canva
The clothes you wear when you work out may do you more harm than helping you to stay healthy as you hit the gym. This is because research has revealed alarming levels of bisphenol A (BPA), a chemical compound linked to significant health risks in several sports wear, including sports bra, leggings, and athletic wear. The Center for Environmental Health (CEH), which is a nonprofit consumer advocacy group has brought these concerns to light, and have raised awareness about the potential danger and damage these sports wear can cause because of the common chemicals used.
Bisphenol A, or BPA is a chemical that is used to make plastics and resins. It is also used in certain fabrics and is known for its endocrine-disrupting properties, which can also interfere with one's hormonal balance. There have been studies, including a 2019 study titled The adverse health effects of bisphenol A and related toxicity mechanisms that have linked BPA exposure to various health problems, including asthma, cardiovascular diseases, obesity, diabetes, and even cancer.
Many of research which have been conducted focus on the ingestion, which can happen when you store food in BPA-lined containers. Among them, some of the more recent studies show that skin absorption is also a pathway. This means when you are handling receipts which are printed on thermal paper, or wear BPA-containing fabrics, the chemical can seep through your skin and enter your bloodstream.
Though it is also true that BPA is exposed from the body within days, however, continuous exposure from multiple sources can be concerning.
CEH also tested popular athletic wear in October 2023 and found BPA levels were exceeding California's safety standards by as much as 22 times.
Testing also showed that top brands contained up to 40 times the permissible limit of BPA.
As far as laws are concerned, under California's Proposition 65, the maximum allowable dose for BPA exposure via skin is 3 micrograms per day. While this law is among the strictest in the United States, it highlights a broader issue of chemical safety in consumer products nationwide.
Ana Soto, an immunologist with decades of research on BPA, even low doses of dermal and oral exposure can combine to create a significant health risk. She also warned that prolonged exposure through fabric, especially when you are exercising, as your pores are open and sweat is present, can in fact, amplify these effects.
BPA can disrupt your body's endocrine system, which is a network of glands and organs that produce hormones that control many bodily functions. These include growth and development, metabolism, and reproduction, to name a few. BPA can mimic natural hormones like estrogen and interfere in those bodily functions.
Studies also link it with obesity and diabetes, respiratory issues, especially asthma risk in school-aged children, cardiovascular diseases, and cancer risks.
There are certain steps you can follow to protect yourself:
Credit: iStock
Nicotine pouches have become popular in the UK, show many studies, this is especially true in the case of young adults.
In fact, a new study done by the researches from University College London (UCL) has found that in the last five years, there has been an increase from 0.1 per cent to 1 per cent of adults using nicotine pouches. This means, around 522,000 more people in the UK have started using the pouches.
The pouches are placed between the lip and gum and it releases nicotine slowly. The pouches are also available in variety of flavors, with sweeteners and plant-based fibers. It does not contain tobacco like vapes do and usually are considered to be a healthier alternative to smoking.
Health and Me ran a fact check on whether it truly is safer than smoking, and here is what we found.
Are Nicotine Pouches Safer Than Smoking?
"This risks are substantially less than some other nicotine products like smoking, because there is no tobacco and there is no combustion," said Dr Harry Tattan-Birch, the lead author of the study, to Mornings with Ridge and Frost.
"And we know the combustion of tobacco is the thing that causes most of the diseases related to smoking," he says.
However, he and his team has warned that while it may not cause serious illness like tobacco can, young people could have a negative impact in their lungs and brains, as they are still in developing stage. This makes them more sensitive to the effects of nicotine, and it could become difficult to stop using it.
A UCL research fellow earlier told Sky News that while nicotine pouches are far less harmful than smoking, their long-term effects remain unclear because they are relatively new. Drawing on what is known about their contents, she noted they are not risk-free, as users are still exposed to some toxic substances, albeit at much lower levels.
Who Are Using These Nicotine Pouches?
Researchers from UCL, supported by Cancer Research UK, analysed survey responses from 127,793 people aged 16 and above across England, Scotland and Wales, collected between October 2020 and March 2025.
Their analysis showed that nicotine pouch use among 16 to 24-year-olds rose to 4% in 2025, up from just 0.7% in 2022. The increase was most pronounced among young men, with one in 13 men in this age group, or 7.5%, reporting use.
Overall, men accounted for 72% of nicotine pouch users between 2022 and 2025, while 47% were under the age of 25. Dr Tattan-Birch said the growth in use has been driven almost entirely by young people, particularly young men, with usage among adults over 35 remaining low and largely unchanged.
He added that this trend also includes children. Since nicotine pouches are not classified as tobacco or vape products, there are currently no age limits. Advertising is also unrestricted, allowing brightly coloured, sweet-flavoured products to appeal to younger audiences.
Do Nicotine Pouches Help Quit Smoking?
The research found that 69 per cent of pouch users were reported using other nicotine products, while 56 per cent of them smoked, as per the survey from January 2022 to March 2025.
1 in 6, which makes it 16 per cent said they never regularly smoked. "Whether nicotine pouches are good or bad for public health depends on who is using them. If it's a young person who would otherwise start smoking, then the use of pouches might help to reduce harm. However, if it's a person who otherwise would not use nicotine at all, then the potential for harm increases," said Tattan-Birch.
Credits: canva
A woman experiencing abdominal discomfort went to her gynecologist for an ultrasound, only to discover something far more startling than a baby. The mom, who shares her story on TikTok under the handle @sandwitchbread, revealed her medical surprise in a video that has now amassed over 1.9 million views. She said she had been struggling with pain and unusual bleeding since giving birth to her two-year-old son and decided to see a gynecologist fearing she might be pregnant again.
During the ultrasound, she noticed something on the screen, but the doctor quickly reassured her it wasn’t a baby. “When my doctor came in to share the results,” the TikToker recalled, “she looked me in the eyes and told me I had a seven-centimeter cyst, about the size of a chicken egg, called a dermoid cyst.”
A dermoid cyst is a pocket of tissue growth that can contain normal body tissues, sometimes including hair, fluid, teeth, or skin. While this TikToker’s cyst was in her uterus, dermoid cysts are most commonly found in the ovaries. They are generally harmless but often require surgical removal. According to the National Cancer Institute, dermoid cysts are present from birth but may not be detected until later in life. These benign tumors originate from embryonic cells that become “trapped” and develop into tissues in the wrong location. Teeth and hair are frequent components, and surgery is usually recommended if the cyst causes symptoms or complications.
Dermoid cysts develop hair and teeth because they arise from trapped embryonic cells (ectoderm) that can grow into skin, hair follicles, sweat glands, and even teeth, instead of forming the tissues normally found in the ovary or skin. Essentially, they are benign tumors made up of mature but misplaced body tissues from the outer layer of the embryo, which normally forms skin and related structures.
Most ovarian dermoid cysts remain symptom-free unless complications occur. When symptoms do appear, the most common one reported is lower abdominal pain.
As the cyst enlarges, it can cause noticeable abdominal swelling and problems with the urinary or digestive system.
In more severe cases, individuals might also experience:
The Office on Women’s Health notes that cysts on the ovaries can also cause:
Some potential complications include:
Rupturing of the cyst: Though rare, ovarian dermoid cysts can burst. If the cyst’s contents leak into the abdominal cavity, it may lead to chronic inflammation of the abdominal lining (peritonitis). In some cases, leakage into the intestines or rectum can result in the material being expelled through the anus.
Ovarian torsion: This occurs when the cyst twists the ligaments holding the ovary in place, which can cut off blood supply to the ovary and fallopian tube.
Infection: The risk of infection is around 1–4%. Severe infections may lead to cyst rupture.
Malignant transformation: Dermoid cysts are almost always benign, but in rare instances, they can become cancerous.
Credits: Canva
A new weight-loss drug often described as the “triple G” treatment because it mimics three hormones linked to hunger and metabolism has delivered striking results in fresh data shared Thursday by its developer, Eli Lilly. In a clinical study involving more than 400 people living with obesity and knee osteoarthritis, the experimental drug retatrutide led to an average weight reduction of 71 pounds, or close to 29% of total body weight, over a period of 16 months, according to figures released by the company. Participants who received retatrutide also reported a 76% drop in knee pain by the end of the study period, based on the same data. So is
Retatrutide is an experimental weight-loss drug developed by Eli Lilly and is widely seen as a next-step advancement beyond current GLP-1-based medications such as semaglutide and tirzepatide. While semaglutide acts on a single hormone pathway and tirzepatide works on two, retatrutide targets three.
It activates GLP-1 and GIP, along with an added glucagon pathway, which is why it is sometimes informally referred to as a “GLP-3” drug. Researchers believe this third pathway could explain the greater weight-loss effects seen so far, although retatrutide remains under investigation and has not yet received FDA approval.
Even without regulatory approval, retatrutide has gained attention among gym enthusiasts, fitness creators, and online weight-loss communities. On platforms like TikTok, where direct searches for #reta or #retatrutide are restricted, users often refer to it using coded terms such as “ratatouille.”
At the same time, the drug has been in the news due to growing concerns about counterfeit versions. Reports from the UK recently revealed that authorities seized more than £250,000 worth of fake weight-loss injection pens labelled as tirzepatide and retatrutide from a hidden factory in Northampton. These products are especially concerning because retatrutide is still in clinical trials and has not been approved for use anywhere in the world.
Retatrutide works by mimicking three hormones that play a role in appetite and metabolism: GLP-1, GIP, and glucagon. In contrast, most weight-loss drugs currently available target only one or two of these pathways. Ozempic and Wegovy, made by Novo Nordisk, copy the effects of GLP-1, a hormone that influences the brain, pancreas, stomach, liver, and muscles, according to the National Institutes of Health.
Mounjaro and Zepbound, on the other hand, act on both GLP-1 and GIP, a hormone involved in blood sugar regulation through insulin stimulation. Retatrutide’s added glucagon effect is key, as glucagon is known to support fat burning, even when the body is at rest. Ozempic and Mounjaro are approved by the FDA for treating Type 2 diabetes, while Wegovy and Zepbound are approved for people with overweight or obesity. As with any prescription drug, it is important for individuals to consult a healthcare professional to determine whether these treatments are appropriate for them.
There is currently no confirmed timeline for when retatrutide might become available by prescription. Its launch will depend on the FDA’s detailed evaluation of clinical trial data once it is formally submitted. Based on current expectations, approval is unlikely before late 2026 and could potentially extend into 2027 or even 2028.
© 2024 Bennett, Coleman & Company Limited